We­govy woes con­tin­ue as man­u­fac­tur­ing is­sues will lead to fur­ther short­age of Novo's obe­si­ty drug

As the new year rapid­ly ap­proach­es, and gyms and health food stores across Amer­i­ca pre­pare for a wave of peo­ple seek­ing weight loss, No­vo Nordisk has an­nounced that it does not ex­pect to meet de­mand for We­govy, its pre­scrip­tion in­jectable weight-loss med­ica­tion for obe­si­ty, un­til the sec­ond half of 2022 in the US.

The short­age comes due to man­u­fac­tur­ing is­sues at a con­tract man­u­fac­tur­er that was tasked with fill­ing sy­ringes for the pens. The news comes just days af­ter No­vo an­nounced that it would in­vest rough­ly $2.58 bil­lion to ex­pand its man­u­fac­tur­ing hub in Kalund­borg, Den­mark with three new fa­cil­i­ties and the ex­pan­sion of a fourth to keep up with the suc­cess of its di­a­betes and obe­si­ty med semaglu­tide, We­govy and Ry­bel­sus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER